Generic Dayvigo Availability
Last updated on Apr 10, 2025.
Dayvigo is a brand name of lemborexant, approved by the FDA in the following formulation(s):
DAYVIGO (lemborexant - tablet;oral)
Is there a generic version of Dayvigo available?
No. There is currently no therapeutically equivalent version of Dayvigo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dayvigo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions and methods for treating insomnia
Patent 10,188,652
Issued: January 29, 2019
Inventor(s): Moline Margaret & Pastino Gina & Akimoto Yurie & Zaima Yasuhiro & Suzuki Nobuya & Yoshida Nobuo
Assignee(s): Eisai R&D Management Co., Ltd.In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Patent expiration dates:
- October 21, 2035✓✓
- October 21, 2035
-
Compositions and methods for treating insomnia
Patent 10,702,529
Issued: July 7, 2020
Inventor(s): Moline Margaret & Pastino Gina & Akimoto Yurie & Zaima Yasuhiro & Suzuki Nobuya & Yoshida Nobuo
Assignee(s): Eisai R&D Management Co., Ltd.In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Patent expiration dates:
- October 21, 2035✓
- October 21, 2035
-
Compositions and methods for treating insomnia
Patent 11,026,944
Issued: June 8, 2021
Inventor(s): Moline Margaret & Pastino Gina & Akimoto Yurie & Zaima Yasuhiro & Suzuki Nobuya & Yoshida Nobuo
Assignee(s): Eisai R&D Management Co., Ltd.In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Patent expiration dates:
- October 21, 2035✓
- October 21, 2035
-
Cyclopropane compound
Patent 8,268,848
Issued: September 18, 2012
Inventor(s): Terauchi Taro & Takemura Ayumi & Doko Takashi & Yoshida Yu & Tanaka Toshiaki & Sorimachi Keiichi & Naoe Yoshimitsu & Beuckmann Carsten & Kazuta Yuji
Assignee(s): Eisai R&D Management Co., Ltd.A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potencial of usefulness for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia:
Patent expiration dates:
- September 20, 2031✓✓✓
- September 20, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 7, 2025 - NEW CHEMICAL ENTITY
- April 20, 2026 - REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E2006-A001-113
More about Dayvigo (lemborexant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (271)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous anxiolytics, sedatives and hypnotics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
